Breakaway From Cancer(R) Launches Newly-Enhanced Website

AmgenAs part of its ongoing mission to serve cancer patients, Amgen's Breakaway from Cancer(R) initiative announced the launch of its enhanced website that provides cancer patients, survivors, and caregivers a 'one-stop shop' of essential resources spanning cancer prevention, education, patient care, advocacy, and financial support.

The website, www.breakawayfromcancer.com, features a powerful new cancer resource navigator tool developed to help cancer patients maneuver through the complicated maze of online information that currently exists. The tool conducts a targeted search based on user-entered criteria from more than 100 hand-selected credible cancer websites to offer patients the information they need.

"Many valuable cancer resources exist, but it is sometimes hard for patients to identify what information applies to them," says Stuart Arbuckle, vice president and general manager, Amgen Oncology. "The enhanced Breakaway from Cancer website pulls information from credible sources and provides a support system and the necessary tools to help patients find exactly the resources they need in their fight against this devastating disease."

Breakaway from Cancer represents a partnership between Amgen and four nonprofit organizations to raise awareness of the broad range of support services available to patients and caregivers to complement those provided by healthcare professionals.

The newly-enhanced website also provides detailed information on the resources and assistance offered by the Breakaway from Cancer nonprofit partners: Prevent Cancer Foundation, Cancer Support Community (formerly known as The Wellness Community), Patient Advocate Foundation, and National Coalition for Cancer Survivorship. Patients are now also able to share and read inspirational stories from across the nation and keep up with the latest news and events from Breakaway from Cancer.

"Nearly everyone has been touched by cancer and felt the burden of this disease; however, far fewer individuals are aware of the full spectrum of help available," said Carolyn R. Aldige, president and founder, Prevent Cancer Foundation. "We are proud to team up with Breakaway from Cancer to offer consolidated resources like those on the new website to support patients."

About Breakaway from Cancer(R)
Founded in 2005 by Amgen as a complementary component to the company's title sponsorship of the Amgen Tour of California, Breakaway from Cancer is designed to help empower people affected by cancer. Breakaway from Cancer supports the services of four nonprofit organizations: Prevent Cancer Foundation, Cancer Support Community (formerly known as The Wellness Community), Patient Advocate Foundation, and National Coalition for Cancer Survivorship. For more information, please visit www.breakawayfromcancer.com.

About Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Most Popular Now

Novartis rises to second place in 2018 Access to M…

Novartis ranked second in the 2018 Access to Medicine Index (ATMi), up from 3rd place in 2016, in recognition of its long-standing efforts to improve worldwide access to ...

MSD is looking for a digital health solution to em…

MSD Lebanon is looking for an external partner to co-create a digital solution that helps oncologists to stay updated with relevant clinical content about cancer. The sol...

Lilly submits New Drug Application to the FDA for …

Eli Lilly and Company (NYSE: LLY) has announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lasmiditan for the acute...

FDA approves new treatment for patients with acute…

The U.S. Food and Drug Administration today approved Daurismo (glasdegib) tablets to be used in combination with low-dose cytarabine (LDAC), a type of chemotherapy, for t...

Sanofi builds focus on rare blood disorders and ca…

Some of the most serious unmet patient needs today are in the field of hematology. Rare blood disorders and blood-related cancers continue to be a major focus of research...

New study reveals probiotics do not help children …

Probiotics are a multibillion-dollar industry with marketing claims of being an effective treatment for a multitude of ailments, including diarrhea. However, findings fro...

Merck and Pfizer provide update on avelumab in pla…

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxor...

U.S. FDA approves Larotrectinib, the first TRK inh…

The U.S. Food and Drug Administration (FDA) has approved larotrectinib, the first oral TRK inhibitor, under the brand name Vitrakvi®. The approval is for the treatment of...

Bristol-Myers Squibb awards "Golden Tickets…

Bristol-Myers Squibb Company (NYSE: BMY) and LabCentral, an innovative, shared laboratory space designed as a launchpad for life-sciences and biotech startups, today anno...

Scorpion venom to shuttle drugs into the brain

The Peptides and Proteins lab at the Institute for Research in Biomedicine (IRB Barcelona) has published a paper in Chemical Communications describing the capacity of a s...

Abbott recommends rejection of below-market mini-T…

Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approx...

AstraZeneca to divest US Synagis rights to Sobi

AstraZeneca has agreed to sell US rights to Synagis (palivizumab) used for the prevention of serious lower respiratory tract infection (LRTI) caused by respiratory syncyt...